Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, potentially limiting patients’ ability to access it.

A short statement from CMS said the agency will consider ways to make Medicare price negotiations, begun under Biden, more ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

At a Senate hearing, Kennedy also said the president has directed him to examine the well-established safety of mifepristone, ...

Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top drugmaker.

The testing company ended last year with $79 million and told investors it will need to raise money to fund its operations and financial commitments.

BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.

States and providers regained access to a key healthcare payments portal late Tuesday amid pushback over the Trump ...

The expansion is a natural progression for Upperton who already develops and manufactures small molecule and biological, ...

The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...

Senators challenged Kennedy, who was nominated as health secretary by President Trump, on his long track record of ...

The startup says its specially constructed RNAi therapies can get deep into brain tissue, yielding new ways to treat ...